Inhibrx Biosciences, Inc.
INBX
$29.53
$0.431.48%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -28.65M | -43.31M | -47.87M | -43.86M | 1.86B |
| Total Depreciation and Amortization | 661.00K | 675.00K | 689.00K | 760.00K | 476.00K |
| Total Amortization of Deferred Charges | 626.00K | 533.00K | 0.00 | 0.00 | 823.00K |
| Total Other Non-Cash Items | 3.21M | 2.88M | 3.45M | 3.46M | -1.95B |
| Change in Net Operating Assets | -5.80M | 3.32M | 4.00K | 9.36M | 35.49M |
| Cash from Operations | -29.95M | -35.90M | -43.72M | -30.28M | -57.36M |
| Capital Expenditure | 0.00 | -21.00K | -16.00K | -247.00K | -1.22M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 0.00 | -21.00K | -16.00K | -247.00K | -1.22M |
| Total Debt Issued | 0.00 | 99.97M | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 0.00 | 0.00 | 32.95M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -125.00K | -- | -- | -- |
| Cash from Financing | 0.00 | 99.84M | 0.00 | 0.00 | 32.95M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -29.95M | 63.92M | -43.74M | -30.53M | -25.62M |